Abstract |
The immunogenicity of a primary series of a new, fully liquid DTaP-IPV-Hep B- PRP-T vaccine ( Hexaxim), administered at 2, 4, 6 months of age in four clinical studies is reviewed. Immunogenicity data at 1 month after the third vaccination were assessed and pooled from a total of 1270 participants (per-protocol population) in four randomized clinical trials in Argentina, Mexico, and Peru. Hepatitis B vaccine was not administered at birth. All seroprotection (D, T, polio-1, -2, -3, Hep B, PRP-T [Hib]), seroconversion (PT and FHA), and vaccine response (PT and FHA) data were high, and were similar to licensed comparators (pooled SP, SC, and VR rates were 97.1-100%, 96.0-97.0%, and 99.7-99.9%, respectively). These data show the good immunogenicity of this new hexavalent vaccine that can provide the opportunity to increase global compliance to complex pediatric vaccination schedules.
|
Authors | Eduardo Santos-Lima, Siham B'Chir, Andrew Lane |
Journal | Vaccine
(Vaccine)
Vol. 31
Issue 9
Pg. 1255-8
(Feb 18 2013)
ISSN: 1873-2518 [Electronic] Netherlands |
PMID | 23246307
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2013. Published by Elsevier Ltd. |
Chemical References |
- Antibodies, Bacterial
- Antibodies, Viral
- Diphtheria-Tetanus-Pertussis Vaccine
- Haemophilus Vaccines
- Hepatitis B Vaccines
- Poliovirus Vaccine, Inactivated
- Vaccines, Combined
- diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine
|
Topics |
- Antibodies, Bacterial
(blood)
- Antibodies, Viral
(blood)
- Argentina
- Diphtheria-Tetanus-Pertussis Vaccine
(administration & dosage, immunology)
- Haemophilus Vaccines
(administration & dosage, immunology)
- Hepatitis B Vaccines
(administration & dosage, immunology)
- Humans
- Infant
- Mexico
- Peru
- Poliovirus Vaccine, Inactivated
(administration & dosage, immunology)
- Vaccines, Combined
(administration & dosage, immunology)
|